Sharon Underberg Net Worth

The estimated Net Worth of Sharon E. Underberg is at least 4.55 百万$ dollars as of 16 February 2024. Ms. Underberg owns over 483 units of Idexx Laboratories stock worth over 2,742,514$ and over the last 10 years she sold IDXX stock worth over 0$. In addition, she makes 1,809,230$ as Corporate Vice President、 General Counsel、 and Corporate Secretary at Idexx Laboratories.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Underberg IDXX stock SEC Form 4 insiders trading

Sharon has made over 15 trades of the Idexx Laboratories stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 483 units of IDXX stock worth 99,952$ on 16 February 2024.

The largest trade she's ever made was exercising 35,251 units of Idexx Laboratories stock on 15 December 2018 worth over 17,282,155$. On average, Sharon trades about 4,296 units every 178 days since 2015. As of 16 February 2024 she still owns at least 5,594 units of Idexx Laboratories stock.

You can see the complete history of Ms. Underberg stock trades at the bottom of the page.

Sharon Underberg biography

Sharon E. Underberg serves as Corporate Vice President, General Counsel, and Corporate Secretary of the Company. Ms. Underberg has been Corporate Vice President, General Counsel and Corporate Secretary since March 2019. She leads IDEXX's legal, compliance and Corporate Secretary groups. Prior to joining IDEXX in February 2019, Ms. Underberg was a member of the Eastman Kodak Company legal team for over 29 years, where she held various senior leadership positions of increasing responsibility, including most recently serving as General Counsel, Secretary and Senior Vice President from January 2015 to January 2019, Deputy General Counsel and Vice President, Legal Department, from September 2014 to January 2015 and Assistant General Counsel and Vice President, Legal Department, from June 2006 to September 2014. Prior to joining Kodak, Ms. Underberg was an attorney in private practice. She received a bachelor's degree in political science from Brandeis University and a J.D. from the University of Pennsylvania School of Law.

What is the salary of Sharon Underberg?

As the Corporate Vice President、 General Counsel、 and Corporate Secretary of Idexx Laboratories, the total compensation of Sharon Underberg at Idexx Laboratories is 1,809,230$. There are 5 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of 8,309,800$.

How old is Sharon Underberg?

Sharon Underberg is 58, she's been the Corporate Vice President、 General Counsel、 and Corporate Secretary of Idexx Laboratories since 2019. There are 10 older and 13 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.

What's Sharon Underberg's mailing address?

Sharon's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.

Insiders trading at Idexx Laboratories

Over the last 22 years, insiders at Idexx Laboratories have traded over 238,711,289$ worth of Idexx Laboratories stock and bought 24,695 units worth 3,109,424$ . The most active insiders traders include Stuart Essig、Johnny D Powers、Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of 4,641,291$. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth 234,685$.

What does Idexx Laboratories do?

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Complete history of Ms. Underberg stock trades at Idexx Laboratories、Eastman Kodak Co

Idexx Laboratories executives and stock owners

Idexx Laboratories executives and other stock owners filed with the SEC include:

• Jonathan Ayers,
  Director
• Jonathan Mazelsky,
  President, Chief Executive Officer, Director
• Brian McKeon,
  Chief Financial Officer, Executive Vice President, Treasurer
• Kathy Turner,
  Corporate Vice President and Chief Marketing Officer
• Jonathan J. Mazelsky,
  Pres, CEO & Director
• Sharon Underberg,
  Corporate Vice President, General Counsel, and Corporate Secretary
• Michael Lane,
  Executive Vice President, General Manager, Reference Laboratories and Information Technology
• Brian P. McKeon,
  CFO, Exec. VP & Treasurer
• Giovani Twigge,
  Chief Human Resource Officer, Corporate Vice President
• Dr. Nimrata Khatra Hunt P.E., Ph.D.,
  Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
• Michael J. Lane,
  Exec. VP and GM of Reference Laboratories & Information Technology
• James F. Polewaczyk,
  Exec. VP & Chief Commercial Officer
• Sharon E. Underberg,
  Exec. VP, Gen. Counsel, & Corp. Sec.
• Lawrence Kingsley,
  Independent Chairman of the Board
• M. Anne Szostak,
  Independent Director
• Daniel Junius,
  Independent Director
• Bruce Claflin,
  Independent Director
• Rebecca Henderson,
  Independent Director
• Sophie Vandebroek,
  Independent Director
• Stuart Essig,
  Independent Director
• Sam Samad,
  Independent Director
• Jonathan W. Ayers,
  Sr. Advisor & Director
• Asha Collins,
  Independent Director
• James Polewaczyk,
  Executive Vice President and Chief Commercial Officer
• Tina Hunt,
  Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations
• Dr. Martin Smith Ph.D.,
  Exec. VP & CTO
• Ken Grady,
  Sr. VP & Chief Information Officer
• Martin Smith,
  Exec. VP & CTO
• Jeffery D. Chadbourne,
  Sr. Director of Accounting & Financial Reporting
• John Hart,
  Sr. VP of Worldwide Operations
• Barry C Johnson,
  Director
• Thomas Craig,
  Director
• William End,
  Director
• Jacqueline Studer,
  CVP, Gen. Counsel & Secretary
• Thomas J Dupree,
  Corporate Vice President
• Michael J Williams,
  Corporate Vice President
• Daniel V Meyaard,
  Corporate Vice President
• Conan R Deady,
  Vice President and Secretary
• Joseph V Vumbacco,
  Director
• William E Iii Brown,
  Corporate Vice President
• William B. Goodspeed,
  Corporate Vice President
• Robert J Murray,
  Director
• Jeffrey Fiarman,
  EVP, GEN COUNSEL & SECRETARY
• Ali Naqui,
  Vice President
• Johnny D Powers,
  Corporate Vice President
• Errol B Desouza,
  Director
• William C Wallen,
  SVP & Chief Scientific Officer
• Quentin J Tonelli,
  Vice President
• S Sam Fratoni,
  Vice President
• Irene C Kerr,
  Corporate Vice President
• Robert S Hulsy,
  Vice President
• Laurel E Labauve,
  Vice President
• Merilee Raines,
  Vice President,CFO & Treasurer
• James L Jr Moody,
  Director
• Jennifer A Joiner,
  Corp VP CAG N American CommOps
• Louis W Pollock,
  Senior Vice President
• Erwin R Jr Workman,
  Executive Vice President
• Nimrata Hunt,
  Executive Vice President
• Irene Chang Britt,
  Director
• Martin Alexander Smith,
  Executive Vice President
• Michael Perkins Johnson,
  EVP and CHRO
• George Fennell,
  SVP, Chief Revenue Officer
• Michael G Erickson,
  Executive Vice President
• Michael Schreck,
  Executive Vice President